Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Q2 Revenues Drop 5 Percent

NEW YORK – Cancer Genetics on Friday reported a 5 percent decrease in second quarter revenues, which it said was primarily due to the timing of discovery services studies.

For the three-months period ended June 30, the Rutherford, New Jersey-based drug-discovery and preclinical oncology services provider posted total revenues of $1.4 million compared to $1.5 million in the same quarter a year ago. The firm's revenues were generated entirely from discovery services following last year's sales of its biopharma services business to Interpace Biosciences for $23.5 million and its clinical laboratory business to siParadigm for $1 million.

Cancer Genetics posted a net loss of $1.7 million, or $.79 per share, for the second quarter versus a net loss of $3.8 million, or $1.98 per share in the same period a year earlier.

The firm's sales, marketing, general, and administrative costs for &A expenses rose 67 percent to $2.5 million from $1.5 million.

Cancer Genetics did not report Q2 R&D expenses.

At the end of the quarter, Cancer Genetics had cash and cash equivalents totaling $2.9 million.

Cancer Genetics' shares dropped 2 percent to $2.94 in morning trading on the Nasdaq.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.